Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland
Krzysztof Łupina, Artur Dziewierz, Jakub Janczura, Zbigniew Siudak · 2026
Read Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland by Krzysztof Łupina, Artur Dziewierz, Jakub Janczura, Zbigniew Siudak (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13395827.txt.
Description
Krzysztof Łupina, Artur Dziewierz, and their co-authors charted how patients switch among diabetes and weight drugs in Poland's largest private health network. Their 2026 study covers prescription records from 2018 to 2025 for the GLP-1 receptor agonist family. Switching means any change of agent between two prescriptions in a row.
The cohort held 42,423 patients with more than one prescription. Overall, 29.7 percent switched at least once and 14.3 percent switched two or more times. A hazard model treated each gap between prescriptions as one chance to switch, measured against injected semaglutide as the baseline drug. Extra analyses varied the time handling and adjusted for elapsed gaps. The results map real world loyalty and churn across this fast growing drug class.
Catalog record
| CREATOR | Krzysztof Łupina, Artur Dziewierz, Jakub Janczura, Zbigniew Siudak |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |